Skip to main content

Advertisement

Table 4 Main grade 3 or higher treatment-related AEs in the present article

From: Emerging therapies for small cell lung cancer

Study Main grade 3 or higher toxicities (over 10%)
NCT01331525 Neurological AEs (10.3%), diarrhea (48.7%), neutrophil count decrease (23.1%), anemia (15.4%), infection (28.2%), and sepsis (10.3%).
CA184-041 ALT (18%) and AST (13%) in concurrent arm vs. fatigue (12%), arthralgia (10%), diarrhea (10%), neutropenia (10%), and anemia (10%) in phased arm.
CA184-156 Neutropenia (24%) and anemia (11%) in chemotherapy plus ipilimumab arm vs. neutropenia (14%) in chemotherapy plus placebo arm.
Impower-133 Neutropenia (22.7%), anemia (14.1%), decreased neutrophil count (14.1%), and thrombocytopenia (10.1%) in chemotherapy plus atezolizumab arm vs. neutropenia (24.5%), anemia (12.2%), and decreased neutrophil count (16.8%) in chemotherapy plus placebo arm.
NCT02359019 Most common adverse events were fatigue, nausea, cough, and dyspnea. One patient developed atrioventricular conduction block and one patient type 1 diabetes. No grade 3 to 5 treatment-related AEs was over 10% of the participants.
CheckMate-032 Two patients who received nivolumab 1 mg/kg plus ipilimumab 3 mg/kg and one patient who received nivolumab 3 mg/kg plus ipilimumab 1 mg/kg died from treatment-related adverse events. No grade 3 to 5 treatment-related AEs was over 10% of the participants.
KEYNOTE-028 Treatment-related AEs were seen in 16 (66.7%) of 24 patients. Two patients experienced grade 3 to 5 treatment-related AEs. No grade 3 to 5 treatment-related AEs was over 10% of the participants.
KEYNOTE-158 Treatment-related AEs occurred in 63 patients (59%) and led to 4 discontinuations and 1 death (pneumonia). No grade 3 to 5 treatment-related AEs was over 10% of the participants.
NCT02261220 Twenty patients (67%) reported ≥ 1 treatment-related AE (TRAE); the most common were fatigue (n = 7 [23%]) and pruritus (n = 7 [23%]). Seven patients (23%) had grade 3/4 TRAEs. No patients discontinued due to TRAEs, and there were no treatment-related deaths.
ECOG-ACRIN 2511 Neutropenia (49%), anemia (19%), leukopenia (19%), and hyponatremia (12%) in chemotherapy plus veliparib arm vs. neutropenia (32%), anemia (12%), and leukopenia (14%) in chemotherapy plus placebo arm.
NCT01638546 Leukopenia (24%), lymphopenia (20%), neutropenia (31%), and thrombocytopenia (50%) in veliparib plus temozolomide arm vs. lymphopenia (26%) in temozolomide plus placebo arm.
NCT02454972 Neutropenia grade (44%)
TRINITY Thrombocytopenia (11%)
ALTER 1202 Grade ≥ 3 TRAEs occurred in 29 (35.8%) of patients in anlotinib arm and 6 (15.4%) in placebo arm.